Analysis of the efficacy, safety and economics of prophylactic antibiotics in high-risk neonates guided by C reaction protein and procalcitonin

doi:10.12092/j.issn.1009-2501.2019.05.013

Abstract

Abstract:

AIM: To evaluate the efficacy, safety and economics of C reaction protein (CRP) and procalcitonin (PCT) in the prevention of the use of antibiotics in high-risk newborns. METHODS:One hundred and twenty-four cases of high risk neonates treated in our hospital from July 2015 to January 2018 were selected as the research subjects and were divided into the control group (62 cases) and the experimental group (62 cases) by random digital tables. The children in the control group were treated with prophylactic antibiotic treatment. The experimental group was treated with selective antibiotics according to the level of CRP and PCT. The positive rate of bacterial culture, the incidence of sepsis and the incidence of adverse reactions were compared between the two groups. RESULTS:There was no statistical difference between the levels of CRP and PCT and the positive rate in the two groups (t/χ2=0.299, -0.461, 0.292, 0.544, 0.186, P=0.766, 0.646, 0.589, 0.461, 0.666). There was no statistical difference in the positive rates of bacteria culture before and after treatment in the two groups (χ2=0.040, 0.287, P=0.842, 0.592), and the positive rate of bacteria culture in the two groups was significantly lower than that before treatment (χ2=47.825, 40.367, P=0.000, 0.000), and the incidence of sepsis in two groups was 12.90% and 14.52%, respectively, which have no statistical significance (χ2=0.068, P=0.794). The NICU treatment in the experimental group was significantly lower than that in the control group (t=2.904, 2.729, 2.152, 5.337, P=0.004, 0.007, 0.033, 0.000), and there was no statistical difference between the two groups (χ2=0.372, P=0.542). The incidence of adverse reactions in the control group was 19.35%, which was significantly higher than that in the experimental group (6.46%, χ2=4.593, P=0.032). CONCLUSION:The effect of preventive use of antibiotics under the guidance of CRP and PCT in high-risk newborns show similar efficay of universal application, which can significantly reduce treatment time and treatment costs, obviously reduce treatment-related adverse reactions and improve the short-term prognosis.

Key words: high-risk newborns, antibiotics, C-reactive protein, procalcitonin, safety

CLC Number:

R722.13+1

HUA Xudan, XIE Hongyi, YU Shufang. Analysis of the efficacy, safety and economics of prophylactic antibiotics in high-risk neonates guided by C reaction protein and procalcitonin[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 561-566.

References

［1］Huynh BT, Padget M, Garin B, et al. Bacterial neonatal sepsis and antibiotic resistance in low-income countries［J］. Lancet, 2016,387(10018):533-534.
［2］Berardi A, Tzialla C, Travan L, et al. Secondary prevention of early-onset sepsis: a less invasive Italian approach for managing neonates at risk［J］. Ital J Pediatr, 2018,44(1):73.
［3］Cantey JB, Wozniak PS, Pruszynski JE, et al. Reducing unnecessary antibiotic use in the neonatal intensive care unit (SCOUT): a prospective interrupted time-series study［J］. Lancet Infect Dis, 2016,16(10):1178-1184.
［4］Mukherjee A, Davidson L, Anguvaa L, et al. NICE neonatal early onset sepsis guidance: greater consistency, but more investigations, and greater length of stay［J］. Arch Dis Child Fetal Neonatal Ed, 2015,100(3):F248-F249.
［5］Escobar GJ, Puopolo KM, Wi S, et al. Stratification of risk of early-onset sepsis in newborns ≥ 34 weeks' gestation［J］. Pediatrics, 2014,133(1):30-36.
［6］《中华医学会中华儿科杂志》编辑委员会. 新生儿败血症诊疗方案［J］. 中华儿科杂志, 2003,41(12):897-899.
［7］Palevsky PM, Liu KD, Brophy PD, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury［J］. Am J Kidney Dis, 2013,61(5):649-672.
［8］Puopolo KM, Benitz WE, Zaoutis TE. Management of neonates born at ≥35 0/7 weeks' gestation with suspected or proven early-onset bacterial sepsis［J］. Pediatrics, 2018,142(6):e20182896.
［9］Korpela K, Zijlmans MA, Kuitunen M, et al. Childhood BMI in relation to microbiota in infancy and lifetime antibiotic use［J］. Microbiome, 2017,5(1):26.
［10］Schulfer A, Blaser MJ. Risks of antibiotic exposures early in life on the developing microbiome［J］. PLoS Pathog, 2015,11(7):e1004903.
［11］韩愈, 杨心宇, 陈晓璐, 等. 地诺前列酮栓联合头孢呋辛治疗足月胎膜早破的临床疗效及对白细胞介素6、C反应蛋白的影响［J］. 中国临床药理学与治疗学, 2018,23(6):700-703.
［12］王剑, 张文. 探讨血清PCT浓度、SVRI、SOFA评分在脓毒症患者中的相关性及临床意义［J］. 中国临床药理学与治疗学, 2017,22(4):443-447.
［13］Nakstad B. The diagnostic utility of procalcitonin, interleukin-6 and interleukin-8, and hyaluronic acid in the Norwegian consensus definition for early-onset neonatal sepsis (EONS)［J］. Infect Drug Resist, 2018,11:359-368.
［14］Mohsen AH, Kamel BA. Predictive values for procalcitonin in the diagnosis of neonatal sepsis［J］. Electron Physician, 2015,7(4):1190-1195.
［15］吕菊红, 马红茹, 李文君. PCT和CRP测定在新生儿败血症早期诊断中的价值［J］. 中国妇幼健康研究, 2012,23(4):463-465.
［16］朱丽坤, 温洁新. Hs-CRP与PCT在新生儿败血症早期诊断及病情评估中的应用［J］. 实用医学杂志, 2016,32(6):1002-1003.
［17］常淑婷, 李贵南, 吴运芹, 等. 降钙素原及超敏C反应蛋白在新生儿败血症诊断中的价值［J］. 中国小儿急救医学, 2013,20(4):411-413.
［18］Wang J, Johnson T, Sahin L, et al. Evaluation of the safety of drugs and biological products used during lactation: workshop summary［J］. Clin Pharmacol Ther, 2017,101(6):736-744.
［19］Campbell SC, Spigarelli MG, Courter J, et al. Metabolic and toxicological considerations for sepsis drug treatments［J］. Expert Opin Drug Metab Toxicol, 2013,9(1):79-89.
［20］Ting JY, Synnes A, Roberts A, et al. Association between antibiotic use and neonatal mortality and morbidities in very low-birth-weight infants without culture-proven sepsis or necrotizing enterocolitis［J］. JAMA Pediatr, 2016,170(12):1181-1187.
［21］Stocker M, van Herk W, El HS, et al. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns)［J］. Lancet, 2017,390(10097):871-881.

[1]	XIAO Yue, LI Tangfei, XUE Qianfu. Analysis of the efficacy and safety of Peg-IFN-α in the treatment of essential thrombocythemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1049-1055.
[2]	JIA Boying, ZHOU Shuang, WAN Liyan, ZHOU Ying, CUI Yimin. Drug-induced dysphagia risk in elder people——A pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) database [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1109-1120.
[3]	LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HUANG Kai. Safety analysis on bioequivalence studies of orally inhaled drug products in healthy Chinese subjects#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1131-1138.
[4]	LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong. Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.
[5]	BAO Jing, CHEN Xiaowen, XIA Liang, ZHAO Yuchen, XIA Ruixiang, XIA Hailong. Clinical efficacy and safety of ixazomib in the treatment of multiple myeloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 782-786.
[6]	PAN Luping, SHI Wujie, SHEN Zhipeng. Efficacy and safety of etoposide combined with carboplatin in children with recurrent medulloblastoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 189-195.
[7]	SHI Lili, LIU Xingan, SHAN Guoyong. Efficacy and safety of apatinib in the further line treatment for patients with advanced colorectal cancer failed after standard therapy and the preliminary analysis of efficacy predictors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1388-1394.
[8]	YANG Haijing, YU Jicheng, WANG Jingjing, LI Nanyang, WU Jufang, ZHANG Hai, XUE Tao, DAI Weiguo, DING Tianling, CAO Guoying. Risk management of biological agents in phase I clinical trials: Case sharing [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 44-48.
[9]	YANG Jingmo, ZHANG Bo, SUN Yancai. Review and economic analysis of preoperative antimicrobial application during the period of type I incision operation in a cancer hospital [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 821-825.
[10]	WANG Haili, GONG Tianxiao, ZHOU Shixia, MEI Jiazhuan, ZHANG Zhongmian. Efficacy and safety of third-line treatment with mesylate apatinib in patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 567-572.
[11]	KANG Hui, YONG Xiaolan, HU Tingting, CHU Bixin, WANG Lantian. Pharmacokinetic study and safety assessment of lacosamide tablets in Chinese healthy subjects under fasting condition [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 192-197.
[12]	YANG Ke, LI Junling, DU Bin, TIAN Zhongqiu, JING Xiujuan. Single-arm,one-center, exploratory clinical trial of albumin-bound paclitaxel second and more line therapy for advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1281-1286.
[13]	LI Wenshu, DONG Huaifu. The value of serum calcitonin in bacterial meningitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1315-1320.
[14]	ZHAO Quanfeng, FU Peishu, MA Huan, ZHAO Suyu, GUO Daihong, TANG Min. Study on liver dysfunction related to voriconazole by automatic surveillance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 43-48.
[15]	CHEN Juanyan, SONG Shuijiang, XU Dongjuan, XU Qiong, LI Hongfei. Effects of fasudil combined with rosuvastatin in the treatment of vascular dementia on patients' cognitive function, C-reactive protein and oxidative stress [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1153-1158.